Berlin Heals Holding AG, a Swiss MedTech company, has secured over $5 million in Series A2 funding to further develop its innovative heart failure treatment. The company is pioneering a less invasive approach to implant its C-MIC (Cardiac Microcurrent) device.
The C-MIC device consists of electrodes connected to a generator delivering a constant microcurrent to the heart. This technology aims to reduce inflammation and reverse the remodeling process associated with heart failure, improving cardiac function. Berlin Heals has conducted successful clinical trials, including a randomized controlled trial, demonstrating the device’s effectiveness.
This latest funding round will primarily support the CMIC-III trial, a first-in-human study involving 10 patients. This trial will test the less invasive implantation procedure, aiming to expedite recovery times and increase accessibility of the therapy. The company also plans to use the funding to prepare for future, larger-scale clinical trials, and to gather data for submission to the FDA for an Investigational Device Exemption.
John Brumfield, CEO of Berlin Heals Holding AG, expressed gratitude for the continued investor support and highlighted the company’s long-term vision to revolutionize heart failure treatment. He emphasized the potential to reach millions of patients globally with this improved approach.
Marko Bagaric, Co-Founder and Board Member, further emphasized the company’s commitment to not just managing symptoms but actively reversing the underlying disease process. He noted that the less invasive implantation method will significantly expand patient access.
Founded in Switzerland in 2014, Berlin Heals Holding AG has already achieved significant milestones. The C-MIC system has received a Breakthrough Device Designation from the FDA and has been accepted into the agency’s Total Product Life Cycle Advisory Program (TAP). The company is also seeking CE regulatory approval for the device.
Related
